Welcome to Oncostellae

Oncostellae is a clinical-stage biopharmaceutical company pioneering the discovery and development of proprietary drug candidates that address high unmet medical needs in immunology, fibrosis and women’s health indications.

Founded in 2013 by a team of medicinal chemists and pharmacologists with a proven track record in drug discovery, Oncostellae brings together deep scientific expertise and an extensive network of collaborators to advance clinical candidates from conception through mid-stage clinical development. Further development and commercialization rights are licensed to established pharmaceutical partners.

OST-122, our locally acting IBD asset, is Phase 2b-ready and open for partnering.